Skip to content
Medxy AI
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • selumetinib
Selumetinib for Adults with NF1-Associated Inoperable Plexiform Neurofibromas: Results from the KOMET Phase 3 Trial
Posted inClinical Updates Wellness & Lifestyle

Selumetinib for Adults with NF1-Associated Inoperable Plexiform Neurofibromas: Results from the KOMET Phase 3 Trial

Posted by By MedXY 08/03/2025
The KOMET phase 3 trial shows selumetinib offers significant tumor response in adults with NF1 and inoperable plexiform neurofibromas, with a manageable safety profile.
Read More
  • Elevated D-Dimer Levels: Beyond Pulmonary Embolism—Uncommon Conditions Many Doctors Overlook
  • Understanding and Managing Alzheimer’s Disease: A Comprehensive Guide
  • Understanding and Managing Seasonal Allergies: A Comprehensive Guide
  • Understanding and Managing Hypertension: A Comprehensive Guide
  • Understanding and Managing Chronic Fatigue Syndrome
  • About us
  • Contact us
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease Antibiotics breast cancer cardiovascular health clinical trial clinical trials Dementia diabetes diet epidemiology exercise FDA FDA approval GLP-1 health healthcare HIV Hypertension immunotherapy lifestyle lifestyle intervention longevity MASLD maternal health men's health mental health nutrition obesity older adults Pediatrics phase 3 trial Pregnancy prevention public health randomized trial semaglutide sexual health stroke treatment type 2 diabetes Vaccine walking weight loss wellness women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top